Table 1.

Demographic and Clinical characteristics of participants (N=413)

	N (%)	Clinical Insomnia		No Clinical Insomnia		P-value
		N	%	N	%
Total	413	82	18.26	367	81.74
Age, years
<55	91 (22.03)	22	24.18	69	75.82	0.083
55–65	196 (47.46)	39	19.90	157	80.10
>65	126 (30.51)	16	12.70	110	87.30
Race/ethnicity
White	341 (82.57)	62	18.18	279	81.82	0.600
Non-white*	72 (17.43)	15	20.83	57	79.17
Educational Level
High school or less	86 (20.82)	16	18.60	70	81.40	0.031
College	181 (43.83)	43	23.76	138	76.24
Graduate or professional school	146 (35.35)	18	12.33	128	87.67
Employment
Full-time	164 (40.00)	27	16.46	137	83.54	0.677
Part-time	61 (14.88)	12	19.67	49	80.33
Not currently	185 (45.12)	37	20.00	148	80.00
Stage
I	167 (40.44)	34	20.36	133	79.64	0.534
II	195 (47.22)	32	16.41	163	83.59
III	51 (12.35)	11	21.57	40	78.43
Chemotherapy
None	158 (38.26)	32	20.25	126	79.75	0.794
Chemotherapy, but no Taxane	105 (25.42)	19	18.1	86	81.90
Chemotherapy included Taxane	150 (36.32)	26	17.33	124	82.67
Radiation therapy
None	125 (30.27)	20	16	105	84.00	0.363
Yes	288 (69.73)	57	19.79	231	80.21
Prior tamoxifen
None	273 (66.10	53	19.41	220	80.59	0.575
Yes	140 (33.90)	24	17.14	116	82.86
Hormon therapy (current)
Letrozole (Femara)	86 (20.82)	12	13.95	74	86.05	0.251
Anastrozole (Arimidex)	278 (67.31)	58	20.86	220	79.14
Exemestane (Aromasin)	49 (11.86)	7	14.29	42	85.71
Time Since Breast Cancer Diagnosis
<2 yrs	132 (31.96)	18	13.64	114	86.36	0.059
2–5	132 (31.96)	33	25	99	75.00
5–10 yrs	102 (24.70)	15	14.71	87	85.29
>=10 yrs	47 (11.38)	11	23.40	36	76.60
Duration of AIs
<1 yr	130 (31.48)	22	16.92	108	83.08	0.662
1–3 yrs	140 (33.90)	25	17.86	115	82.14
>3 yrs	143 (34.62)	30	20.98	113	79.02

^*Non-white: mostly black